General Information of Drug (ID: DM57HZW)

Drug Name
SB-332235 Drug Info
Synonyms
1-(4-Chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; 276702-15-9; SB 332235; UNII-5HLP8UVL8M; 5HLP8UVL8M; CHEMBL3819292; WTLRWOHEKQGKDS-UHFFFAOYSA-N; SCHEMBL1535901; sb332235; MolPort-042-624-550; ZINC3990011; BDBM50182254; 1-(4-chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; AKOS027470251; N-(4-Chloro-2hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) urea; n-(4-chloro-2-hydroxy-3-aminosulfonylphenyl)-n'-(2,3-dichlorophenyl)urea; N-(4-Chloro-2-hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) Urea; N-(3-(aminosulfonyl)-4-chloro-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl) urea
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
9887803
CAS Number
CAS 276702-15-9
TTD Drug ID
DM57HZW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [3]
Clotrimazole DMMFCIH Cutaneous candidiasis 1F23.14 Approved [4]
Reparixin DMVBA7I Pancreatic islet transplantation failure NE84 Phase 3 [3]
SCH-527123 DMPUAOE Chronic obstructive pulmonary disease CA22 Phase 2 [5]
SB-265610 DM8TKG5 Asthma CA23 Phase 2 [2]
AZD-5069 DM3JSFK Asthma CA23 Phase 2 [6]
PS-938285 DMHZIFJ Chronic obstructive pulmonary disease CA22 Phase 2 [7]
GSK1325756 DMA6RBF Chronic obstructive pulmonary disease CA22 Phase 2 [8]
SB-656933 DMCY785 Chronic obstructive pulmonary disease CA22 Phase 2 [9]
RIST4721 DMA3DKO Hidradenitis suppurativa ED92.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014165)
2 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
3 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
4 Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
5 CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
6 Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
7 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.